[In Press] Patient demographics and management landscape of metastatic colorectal cancer in the third-line setting: real-world data in an Australian population

摘要: Background Colorectal cancer is the third most common cancer and second leading cause of cancer mortality in Australia, thus carrying a significant disease burden. Aims This analysis aims to explore real-world treatment landscape of metastatic colorectal cancer in the third-line setting. Methods We retrospectively analysed treatment of recurrent and advanced colorectal cancer (TRACC) registry database from 2009 onwards. Patients treated with palliative intent who progressed after two lines of therapies were included. One treatment line was defined as any combination of systemic therapy given until progression. Results Out of 1820 patients treated palliatively, 32%(590 patients) met study criteria. Of these, 43%(254 patients) proceeded to third-line therapy, equating to 14% of all metastatic patients. In KRAS mutant or unknown tumours (97 patients), fluoropyrimidine (FP)-oxaliplatin combination was the most …